Although detailed results have not yet been published, preliminary reports indicate that the MTBR-tau-243 fragment, an emerging CSF biomarker for tau tangles, declined by 30% to 70% following antibody treatment in AD patients, providing the therapeutic potential of targeting MTBR domains in tauopathies (Clinical Trials on Alzheimer’s Disease conference (CTAD) 2024). The gene discussed is MAPT; the disease is tauopathy.